Multidimensional Analysis of Quality of Life in Patients with Chronic Non-Cancer Pain and Short- and Long-Term Intrathecal Analgesic Therapy
Metadatos
Mostrar el registro completo del ítemAutor
Sánchez-García, Manuel Alejandro; Alcázar-Navarrete, Bernardino; Cortiñas Sáenz, Manuel; Cordero Tous, Nicolás; Gálvez Mateos, RafaelEditorial
MDPI
Materia
long-term spinal pain chronic low back pain intrathecal infusion thecal infusion systems intrathecal drug delivery systems
Fecha
2024-08-18Referencia bibliográfica
Sánchez García, M.A. et. al. Healthcare 2024, 12, 1870. [https://doi.org/10.3390/healthcare12181870]
Resumen
Background: Intrathecal drug delivery (IDD) is part of the fourth analgesic step. Evidence
on the quality of life of patients with refractory chronic non-cancer pain (CNCP) using these devices
and their long-term outcomes is scarce. This study aims to evaluate patients with IDD to assess their
HRQoL. Additionally, the study seeks to understand the patients’ satisfaction with the treatment and
changes in pain magnitude over time. Methods: Adult patients with CNCP and intrathecal drug
delivery systems (IDDS) were included. The study population was divided into two groups: less
than and more than 15 years of treatment. HRQoL was analyzed using validated questionnaires.
Pain reduction was assessed using the visual analog scale (VAS), and treatment satisfaction was
evaluated using the Patient Global Impression of Improvement scale. Results: The results indicate
a poor HRQoL in IDD patients, with better scores in the group with ≥15 years of treatment. Pain
reduction was similar in both groups, and patients reported a positive satisfaction level with the
treatment. Conclusions: HRQoL in CNCP patients is severely affected. Long-term IDD patients have
a similar or even better HRQoL in some respects compared to those with shorter follow-ups. IDD
patients experienced pain reduction, with most feeling better or much better.